Weaver Consulting Group Bio Line Rx Ltd. Transaction History
Weaver Consulting Group
- $293 Million
- Q4 2024
A detailed history of Weaver Consulting Group transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Weaver Consulting Group holds 11,000 shares of BLRX stock, worth $36,960. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 29,745
63.02%
Holding current value
$36,960
Previous $16,000
87.5%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding BLRX
# of Institutions
40Shares Held
3.36MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$2.91 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.74 Million4.05% of portfolio
-
Envestnet Asset Management Inc239KShares$803,6640.0% of portfolio
-
Morgan Stanley New York, NY198KShares$663,7240.0% of portfolio
-
Values First Advisors, Inc.166KShares$559,2680.02% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $207M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...